Aileron Total Current Liabilities vs Non Currrent Assets Other Analysis

ALRN Stock

USD 2.74 0.18 7.03%

Aileron Therapeutics financial indicator trend analysis is way more than just evaluating Aileron Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aileron Therapeutics is a good investment. Please check the relationship between Aileron Therapeutics Total Current Liabilities and its Non Currrent Assets Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.

Total Current Liabilities vs Non Currrent Assets Other

Total Current Liabilities vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aileron Therapeutics Total Current Liabilities account and Non Currrent Assets Other. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Aileron Therapeutics' Total Current Liabilities and Non Currrent Assets Other is -0.34. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Aileron Therapeutics, assuming nothing else is changed. The correlation between historical values of Aileron Therapeutics' Total Current Liabilities and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Aileron Therapeutics are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Total Current Liabilities i.e., Aileron Therapeutics' Total Current Liabilities and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

-0.34

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Aileron Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aileron Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most indicators from Aileron Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aileron Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.At this time, Aileron Therapeutics' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 29th of November 2024, Enterprise Value Multiple is likely to grow to 0.22, while Selling General Administrative is likely to drop about 10.4 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	26.6M	27.6M	16.3M	24.5M
Cost Of Revenue	121K	169K	119K	113.1K

Total Operating Expenses Cost Of Revenue

Aileron Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Short Term Investments	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Non Current Liabilities Total	Property Plant And Equipment Gross
Total Assets		0.52	0.47	0.5	0.64	0.57	-0.71	0.23	0.45	-0.27	0.37	-0.03	0.66	0.21	0.42	-0.22	0.37	0.76	-0.13	-0.12	-0.67	0.92	0.4	0.71	-0.55	-0.08
Other Current Liab	0.52		0.69	0.65	0.69	0.67	-0.58	0.53	0.45	0.35	0.51	0.26	0.66	0.37	0.59	0.16	0.51	0.51	0.08	0.11	-0.51	0.34	-0.2	0.43	-0.63	0.14
Total Current Liabilities	0.47	0.69		0.78	0.83	0.78	-0.64	0.71	0.36	0.28	0.48	0.25	0.79	0.45	0.72	0.01	0.49	0.45	0.54	0.57	-0.32	0.29	-0.34	0.35	-0.77	0.59
Total Stockholder Equity	0.5	0.65	0.78		0.96	1.0	-0.77	0.51	-0.02	-0.1	0.63	0.54	0.93	0.67	0.92	-0.47	0.65	0.64	0.27	0.3	-0.06	0.27	-0.44	0.58	-0.98	0.33
Other Liab	0.64	0.69	0.83	0.96		0.97	-0.89	0.58	0.14	-0.1	0.48	0.29	0.99	0.61	0.93	-0.37	0.49	0.76	0.26	0.29	-0.25	0.48	-0.31	0.69	-0.98	0.33
Net Tangible Assets	0.57	0.67	0.78	1.0	0.97		-0.81	0.5	0.02	-0.12	0.61	0.49	0.95	0.65	0.91	-0.47	0.63	0.68	0.25	0.27	-0.12	0.35	-0.38	0.63	-0.99	0.31
Retained Earnings	-0.71	-0.58	-0.64	-0.77	-0.89	-0.81		-0.49	-0.16	0.27	-0.28	-0.06	-0.94	-0.51	-0.89	0.24	-0.3	-0.95	-0.02	-0.04	0.37	-0.64	0.2	-0.92	0.84	-0.09
Accounts Payable	0.23	0.53	0.71	0.51	0.58	0.5	-0.49		0.55	0.1	0.38	0.09	0.55	0.26	0.54	0.15	0.38	0.34	0.25	0.27	-0.51	0.09	-0.47	0.25	-0.49	0.29
Cash	0.45	0.45	0.36	-0.02	0.14	0.02	-0.16	0.55		0.15	0.12	-0.3	0.12	-0.2	-0.04	0.43	0.11	0.15	-0.07	-0.06	-0.88	0.43	0.23	0.06	0.02	-0.05
Other Assets	-0.27	0.35	0.28	-0.1	-0.1	-0.12	0.27	0.1	0.15		-0.12	-0.12	-0.17	-0.34	-0.16	0.65	-0.14	-0.4	0.45	0.46	-0.01	-0.24	-0.01	-0.44	0.12	0.45
Cash And Short Term Investments	0.37	0.51	0.48	0.63	0.48	0.61	-0.28	0.38	0.12	-0.12		0.86	0.43	0.41	0.43	-0.25	1.0	0.3	-0.08	-0.07	-0.2	-0.01	-0.38	0.27	-0.49	-0.06
Short Term Investments	-0.03	0.26	0.25	0.54	0.29	0.49	-0.06	0.09	-0.3	-0.12	0.86		0.25	0.43	0.37	-0.38	0.87	0.08	-0.01	0.0	0.29	-0.39	-0.58	0.08	-0.39	0.0
Capital Surpluse	0.66	0.66	0.79	0.93	0.99	0.95	-0.94	0.55	0.12	-0.17	0.43	0.25		0.63	0.94	-0.36	0.45	0.82	0.19	0.22	-0.27	0.52	-0.3	0.76	-0.97	0.26
Other Current Assets	0.21	0.37	0.45	0.67	0.61	0.65	-0.51	0.26	-0.2	-0.34	0.41	0.43	0.63		0.67	-0.43	0.45	0.42	0.05	0.07	0.1	0.04	-0.51	0.37	-0.66	0.08
Other Stockholder Equity	0.42	0.59	0.72	0.92	0.93	0.91	-0.89	0.54	-0.04	-0.16	0.43	0.37	0.94	0.67		-0.34	0.45	0.77	0.23	0.26	-0.05	0.25	-0.55	0.74	-0.93	0.3
Total Liab	-0.22	0.16	0.01	-0.47	-0.37	-0.47	0.24	0.15	0.43	0.65	-0.25	-0.38	-0.36	-0.43	-0.34		-0.27	-0.22	-0.12	-0.1	-0.4	-0.13	0.0	-0.25	0.47	-0.11
Total Current Assets	0.37	0.51	0.49	0.65	0.49	0.63	-0.3	0.38	0.11	-0.14	1.0	0.87	0.45	0.45	0.45	-0.27		0.32	-0.08	-0.06	-0.19	-0.01	-0.4	0.28	-0.51	-0.05
Common Stock	0.76	0.51	0.45	0.64	0.76	0.68	-0.95	0.34	0.15	-0.4	0.3	0.08	0.82	0.42	0.77	-0.22	0.32		-0.2	-0.19	-0.42	0.69	-0.08	0.99	-0.69	-0.13
Property Plant Equipment	-0.13	0.08	0.54	0.27	0.26	0.25	-0.02	0.25	-0.07	0.45	-0.08	-0.01	0.19	0.05	0.23	-0.12	-0.08	-0.2		1.0	0.34	-0.11	-0.08	-0.23	-0.28	1.0
Property Plant And Equipment Net	-0.12	0.11	0.57	0.3	0.29	0.27	-0.04	0.27	-0.06	0.46	-0.07	0.0	0.22	0.07	0.26	-0.1	-0.06	-0.19	1.0		0.33	-0.11	-0.11	-0.21	-0.3	1.0
Net Debt	-0.67	-0.51	-0.32	-0.06	-0.25	-0.12	0.37	-0.51	-0.88	-0.01	-0.2	0.29	-0.27	0.1	-0.05	-0.4	-0.19	-0.42	0.34	0.33		-0.64	-0.29	-0.34	0.09	0.3
Non Current Assets Total	0.92	0.34	0.29	0.27	0.48	0.35	-0.64	0.09	0.43	-0.24	-0.01	-0.39	0.52	0.04	0.25	-0.13	-0.01	0.69	-0.11	-0.11	-0.64		0.61	0.64	-0.37	-0.07
Non Currrent Assets Other	0.4	-0.2	-0.34	-0.44	-0.31	-0.38	0.2	-0.47	0.23	-0.01	-0.38	-0.58	-0.3	-0.51	-0.55	0.0	-0.4	-0.08	-0.08	-0.11	-0.29	0.61		-0.07	0.37	-0.1
Common Stock Shares Outstanding	0.71	0.43	0.35	0.58	0.69	0.63	-0.92	0.25	0.06	-0.44	0.27	0.08	0.76	0.37	0.74	-0.25	0.28	0.99	-0.23	-0.21	-0.34	0.64	-0.07		-0.64	-0.16
Non Current Liabilities Total	-0.55	-0.63	-0.77	-0.98	-0.98	-0.99	0.84	-0.49	0.02	0.12	-0.49	-0.39	-0.97	-0.66	-0.93	0.47	-0.51	-0.69	-0.28	-0.3	0.09	-0.37	0.37	-0.64		-0.34
Property Plant And Equipment Gross	-0.08	0.14	0.59	0.33	0.33	0.31	-0.09	0.29	-0.05	0.45	-0.06	0.0	0.26	0.08	0.3	-0.11	-0.05	-0.13	1.0	1.0	0.3	-0.07	-0.1	-0.16	-0.34

Click cells to compare fundamentals

Aileron Therapeutics Account Relationship Matchups

Aileron Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	26.5M	16.3M	48.5M	22.0M	106.0M	111.3M
Other Current Liab	352K	2.2M	3.1M	1.6M	3.1M	2.4M
Total Current Liabilities	5.8M	4.0M	4.5M	3.4M	4.4M	4.5M
Total Stockholder Equity	16.0M	12.2M	43.9M	18.6M	6.9M	7.2M
Net Tangible Assets	16.0M	12.2M	43.9M	18.6M	21.4M	22.5M
Retained Earnings	(198.1M)	(219.3M)	(245.5M)	(272.8M)	(288.5M)	(302.9M)
Accounts Payable	1.5M	1.6M	1.2M	1.7M	1.2M	1.5M
Cash	5.3M	7.0M	3.6M	5.2M	17.3M	10.1M
Cash And Short Term Investments	18.3M	13.8M	45.9M	21.2M	17.3M	25.2M
Short Term Investments	38.9M	10.1M	13.0M	6.8M	42.3M	16.0M
Capital Surpluse	184.8M	188.1M	214.1M	231.4M	266.1M	279.4M
Other Current Assets	1.2M	2.5M	2.2M	631K	953K	1.2M
Other Stockholder Equity	214.1M	231.4M	289.3M	291.4M	204.0M	171.5M
Total Liab	10.4M	4.2M	4.6M	3.4M	7.7M	7.3M
Total Current Assets	19.6M	16.3M	48.2M	21.9M	18.3M	26.4M
Property Plant Equipment	6.4M	15K	280K	110K	126.5K	120.2K
Property Plant And Equipment Net	6.4M	15K	280K	110K	19K	18.1K
Net Debt	(279K)	(6.7M)	(3.4M)	(5.2M)	(17.3M)	(18.1M)
Non Current Assets Total	6.9M	15K	304K	134K	87.7M	92.1M
Non Currrent Assets Other	694K	1.2M	568K	24K	2.2M	2.3M
Common Stock Shares Outstanding	1.2M	1.7M	4.4M	4.5M	4.6M	4.8M
Liabilities And Stockholders Equity	26.5M	16.3M	48.5M	22.0M	106.0M	111.3M
Non Current Liabilities Total	4.6M	219K	69K	1.8M	3.3M	3.2M
Property Plant And Equipment Gross	6.4M	15K	492K	380K	377K	358.2K
Accumulated Other Comprehensive Income	7K	(2K)	(13K)	(48K)	(63K)	(66.2K)
Net Invested Capital	16.0M	12.5M	43.9M	18.6M	6.9M	6.5M
Net Working Capital	13.7M	12.4M	43.7M	18.5M	13.9M	18.9M
Short Long Term Debt Total	5.0M	387K	162K	33K	48K	45.6K
Capital Lease Obligations	5.0M	0.0	162K	33K	48K	45.6K

Pair Trading with Aileron Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Aileron Stock

0.66	EWTX	Edgewise Therapeutics	Pair Corr
0.72	BHC	Bausch Health Companies	Pair Corr

Moving against Aileron Stock

0.52	ELAN	Elanco Animal Health Potential Growth	Pair Corr
0.48	INAB	In8bio Inc	Pair Corr

The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.

The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Aileron Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aileron Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aileron Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aileron Therapeutics Stock:

How To Invest In Aileron

Details

Is Aileron Stock a good investment?

Details

What is Aileron Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.88)

Return On Assets

(0.26)

Return On Equity

(0.44)

The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aileron Total Current Liabilities vs Non Currrent Assets Other Analysis

Total Current Liabilities vs Non Currrent Assets Other

Total Current Liabilities vs Non Currrent Assets Other Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Non Currrent Assets Other

Aileron Therapeutics fundamental ratios Correlations

Aileron Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aileron Therapeutics fundamental ratios Accounts

Pair Trading with Aileron Therapeutics

Moving together with Aileron Stock

Moving against Aileron Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 1.0	Property Plant Equipment
Property Plant And Equipment Gross	+ 1.0	Property Plant Equipment
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Capital Surpluse	+ 0.99	Other Liab

Non Current Liabilities Total	- 0.99	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Other Liab
Non Current Liabilities Total	- 0.98	Total Stockholder Equity
Non Current Liabilities Total	- 0.97	Capital Surpluse
Common Stock	- 0.95	Retained Earnings
Capital Surpluse	- 0.94	Retained Earnings